13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
35 檔
38.8%
At the close of Q1 2024, Great Point Partners LLC disclosed equity holdings valued at approximately $529.1M, spread across 35 reported holdings.
During Q1 2024, Great Point Partners LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NGNE | Neurogene Inc | Stock-Other | 7.97% | -0.23% | +1.01% | |
| 2 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 6.97% | — | -69.53% | |
| 3 | URGN | UroGen Pharma Ltd. | Stock-Other | 6.13% | — | — | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 5.55% | +15.22% | NEW | |
| 5 | EOLS | Evolus Inc | Stock-Other | 5.35% | — | +22.50% | |
| 6 | PLRX | Pliant Therapeutics Inc | Stock-Other | 4.30% | — | +1.57% | |
| 7 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.14% | -7.23% | EXIT | |
| 8 | ✓ | Stock-Other | 4.09% | — | -14.46% | ||
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.64% | — | — | |
| 10 | ANAB | Anaptysbio Inc | Stock-Other | 3.43% | — | — | |
| 11 | ESPR | Esperion Therapeutics Inc | Stock-Other | 3.34% | — | — | |
| 12 | INSM | Insmed Inc | Stock-Healthcare | 3.28% | — | +243.31% | |
| 13 | ACLXGBX | Arcellx Inc | Stock-Other | 3.25% | — | +521.58% | |
| 14 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.06% | — | -23.98% | |
| 15 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.93% | — | — | |
| 16 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.92% | — | — | |
| 17 | OTLK | Outlook Therapeutics Inc | Stock-Other | 2.75% | — | — | |
| 18 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.75% | — | +16.79% | |
| 19 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.45% | — | +146.96% | |
| 20 | DVAX | Dynavax Technologies CORP | Stock-Other | 2.45% | — | — | |
| 21 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.21% | — | -59.56% | |
| 22 | ✓ | Optinose Inc | Stock-Other | 2.00% | — | -0.61% | |
| 23 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.86% | — | — | |
| 24 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.62% | — | +35.62% | |
| 25 | ✓ | Merus N V | Stock-Other | 1.57% | — | +1016.44% | |
| 26 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 1.53% | — | — | |
| 27 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.34% | — | — | |
| 28 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.16% | — | -60.75% | |
| 29 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.16% | — | — | |
| 30 | PBYI | Puma Biotechnology Inc | Stock-Other | 1.11% | — | +22.90% | |
| 31 | ✓ | Zura Bio LTD | Stock-Other | 1.10% | -1.07% | -16.31% | |
| 32 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.81% | — | — | |
| 33 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.74% | — | — | |
| 34 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 35 | ARVN | Arvinas Inc | Stock-Other | 0.46% | — | -69.62% |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 35 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NGNE, NVLSEUR, URGN) accounted for 38.8% of total reported equity market value during Q1 2024.
During Q1 2024, Great Point Partners LLC's top holdings by market value included NGNE (8.0%)、NVLSEUR (7.0%)、URGN (6.1%). The largest single position, NGNE, represented 8.0% of total portfolio value.
In Q1 2024, Great Point Partners LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.